Analysts think VKTX stock price could increase by 169%
Aug 09, 2025, 11:25 AM
-28.98%
What does VKTX do
Viking Therapeutics, based in San Diego, develops therapies for metabolic and endocrine disorders, including VK2809 for NASH, VK0214 for X-ALD, and VK2735 for metabolic issues. The company went public on April 29, 2015, and has 28 employees.
20 analysts think VKTX stock price will increase by 169.20%. The current median analyst target is $102.00 compared to a current stock price of $37.89. The lowest analysts target is $33.33 and the highest analyst target is $131.25.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
